Resolvin E1

Resolvin E1 (RvE1) is a trihydroxy eicosapentaenoic acid metabolite that has been identified in mouse inflammatory exudates and in human plasma when subjects are treated with both aspirin and supplemental EPA.[1],[2],[3] RvE1 is an anti-inflammatory EPA metabolite that has been shown to promote inflammatory resolution in numerous disease models, including experimental colitis, asthma, atherosclerosis, type 2 diabetes, and HSV-1-induced stromal keratitis.[4],[5],[6],[7],[8],[9],[10],[11]
Resolvin E1（RvE1）是一种三羟基二十碳五烯酸代谢物，在小鼠炎症渗出物和人类血浆中已被鉴定，当受试者同时接受阿司匹林和补充的EPA时可发现RvE1的存在。RvE1是一种抗炎EPA代谢产物，已被证明在多种疾病模型中促进炎症的解决，包括实验性结肠炎，哮喘，动脉粥样硬化，2型糖尿病和HSV-1引起的角膜炎

Reference:
[1]. Serhan, C.N., Clish, C.B., Brannon, J., et al. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. Journal of Experimental Medicine 192(8), 1197-1204 (2000).
[2]. Serhan, C.N., Hong, S., Gronert, K., et al. Resolvins: A family of bioactive products of ω-3 fatty acid transformation circuits by aspirin treatment that counter proinflammation signals. J. Exp. Med. 196(8), 1025-1037 (2002).
[3]. Arita, M., Bianchini, F., Aliberti, J., et al. Sterochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. Journal of Experimental Medicine 201(5), 713-722 (2005).
[4]. Flower, R.J., and Perretti, M. Controlling inflammation: A fat chance? Journal of Experimental Biology 201(5), 671-674 (2005).
[5]. Arita, M., Yoshida, M., Hong, S., et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences of the United States of America 102(21), 7671-7676 (2005).
[6]. Aoki, H., Hisada, T., Ishizuka, T., et al. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochemical and Biophysical Research Communications 367, 509-515 (2008).
[7]. Haworth, O., Cernadas, M., and Levy, B.D. NK cells are effectors for resolvin E1 in the timely resolution of allergic airway inflammation. Journal of Immunology 186(11), 6129-6135 (2011).
[8]. Campbell, E.K., MacManus, C.F., Kominsky, D.J., et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proceedings of the National Academy of Sciences of the United States of America 107(32), 14298-14303 (2010).
[9]. Hasturk, H., Abdallah, R., Kantarck, A., et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology 35(5), 1123-1133 (2015).
[10]. Herrera, N.S., Hasturk, H., Kantarck, A., et al. Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infection and Immunity 83(2), 792-801 (2015).
[11]. Rajasagi, N.K., Reddy, P.B.J., Suryawanshi, A., et al. Controlling herpes simplex virus-induced ocular inflammatory lesions with the lipid-derived mediator resolvin E1. Journal of Immunology 186(3), 1735-1746 (2011).